异基因干细胞移植后急性髓系白血病复发的治疗进展  

Progress in the treatment of acute myeloid leukemia recurrence after allogeneic stem cell transplantation

作　　者：千晨静 刘芳[1] 王晴晴 杨菲燕 夏凌辉[1] 洪梅[1] QIAN Chenjing;LIU Fang;WANG Qingqing;YANG Feiyan;XIA Linghui;HONG Mei(Institute of Hematology,Union Hospital,Tongji Medical College of Huazhong University of Science and Technology,Hubei Wuhan 430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院血研所,湖北武汉430022

出　　处：《现代肿瘤医学》2021年第9期1610-1614,共5页Journal of Modern Oncology

基　　金：国家自然科学基金面上项目(编号:81974003)。

摘　　要：急性髓系白血病(AML)是一种表型和预后异质性造血干细胞疾病,在接受强化化疗和/或异基因造血干细胞移植(allo-HSCT)的患者中可能得到治愈。随着测序技术的发展揭示了大量分子信息,显著改善了我们对AML基础病理生理学的理解并促进了靶向疗法的发展,目前正在研究几种靶向分子改变的小分子,如FLT3抑制剂、异柠檬酸脱氢酶(IDH)突变或抗凋亡b细胞淋巴瘤2(BCL-2)蛋白抑制剂。尽管取得了这些进展,许多患者在疾病过程中仍将进行异基因造血干细胞移植,根据疾病和风险状况,高达一半的患者最终将在移植后复发。在此,我们回顾了allo-HSCT治疗后AML患者复发后的治疗方法并作一综述。Acute myeloid leukemia(AML)is a phenotypic and prognostic heterogeneous hematopoietic stem cell disease that may be cured in patients receiving intensive chemotherapy and/or allogeneic hematopoietic stell cell transplantation(allo-HSCT).New advances in sequencing techniques have revealed a wealth of molecular information that has significantly improved our understanding of the underlying pathophysiology of AML and facilitated the development of targeted therapies.Several mall molecules that are targeted for molecular change are currently being investigated,such as FLT3 inhibitors,isocitrate dehydrogenase(IDH)mutations,or anti-apoptotic b-cell lymphoma 2(bcl-2)proteins.Despite these advances,many patients will receive allogeneic stem cell transplants during the course of the disease,and up to half will eventually relapse after the transplant,depending on the disease and risk status.Here,we review the strategies and methods of post-relapse treatment in AML patients treated with allo-HSCT.

关 键 词：急性髓系白血病 异基因造血干细胞移植 复发 治疗 

分 类 号：R733.7[医药卫生—肿瘤]